All subcategories » trial from other registries
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study - Phase 4 - Not yet recruiting
ongoing trials trial from other registries
Details- 2022
- Chris Goss|University of Washington|Medical University of South Carolina|Cystic Fibrosis Foundation|Seattle Children's Hospital
Evaluation the effects of camel milk in spirometry parameters in over 6 yearâs children with Cystic Fibrosis lung disease - Recruiting
ongoing trials trial from other registries
Details- 2022
Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis - Phase 2 - Recruiting
ongoing trials trial from other registries
Details- 2022
- University of Kansas Medical Center
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation - Phase 3 - Not yet recruiting
ongoing trials trial from other registries
Details- 2022
- Vertex Pharmaceuticals Incorporated
A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation
ongoing trials trial from other registries
Details- 2021
CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) - Phase 1|Phase 2 - Not yet recruiting
ongoing trials trial from other registries
Details- 2021
- Yale University
A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection - Phase 2|Phase 3 - Recruiting
ongoing trials trial from other registries
Details- 2021
- Bambino Gesù Hospital and Research Institute|University of Exeter|Radboud University|Consorzio per Valutazioni Biologiche e Farmacologiche
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection - Phase 1|Phase 2 - Not yet recruiting
ongoing trials trial from other registries
Details- 2021
- BiomX, Inc.
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation
ongoing trials trial from other registries
Details- 2021